Pharma and Nutraceuticals

BerGen Bio AS
BerGen Bio AS offers novel validated drug candidates and therapeutic targets to the global biotechnology and pharmaceutical industry. In addition, BerGenBio offers, as a service to the same sector, a unique (RNAi based) approach to drug target discovery and validation which translates into increased candidate success and reduced time to market. The company’s business model is focused on the sale of validated drug Leads and Targets which are primarily developed in-house but also include those arising from co-development contracts, whilst the Service operations finance the company’s running costs.

www.bergenbio.com

APIM Therapeutics AS
APIM Therapeutics AS develop novel peptide drugs which have the potential of improving the action of a wide range of chemotherapeutic agents, including top selling DNA-interacting drugs, currently used for the treatment of several types of cancer.

C10 Pharma AS
C10 Pharma develops semisynthetic antibiotic compounds with activity against a broad spectrum of antibiotic resistant bacteria. The new compounds are based on research from The University of Oslo and are modifications of already existing antibiotic compounds that are in daily use in modern medicine. This will speed up the regulatory processes and lead to that the new compounds may be approved for use in the treatment of life-threatening infections within few years. Sarsia Seed is invested in C10 Pharma AS through a co-investment with the Danish investment fund NovoSeeds.

Prophylix Pharma AS
Prophylix Pharma develops a prophylactic treatment for the condition Neonatal Alloimmune Trombocytopenia (NAIT) in newborns. NAIT is caused by tissue incompatibility between a mother and her child and causes severe illness and often mortality in newborns. The planned treatment will be administered as a single dose injection to the mother immediately after delivery and the treatment has the potential to prevent development of NAIT in subsequent pregnancies. The technological basis of Prophylix Pharma comes from research at The University Hospital of North Norway and Ullevål University Hospital.  Sarsia Seed is invested in Prophylix Pharma AS through a co-investment with the seed fund Norinnova Invest AS.

www.prophylixpharma.com

Vaccibody AS

Vaccibody AS develops vaccines based on a novel proprietary concept with the potential to not only improve the efficacy of traditional prophylactic vaccines but also allows for the therapeutic use of vaccines in the active treatment i.e. post-infection, of problematic infectious diseases like herpes, HIV and influenza. The company’s technology also allows for the development of therapeutic vaccines against certain types of cancer.

www.vaccibody.com

Avexxin AS 

Avexxin develops anti-inflammatory agents for treatment of psoriasis and other inflammation related conditions. The company aims to develop better and more cost-effective drugs than those available today. Sarsia Seed participates as a co-investor together with Karolinska Development, the commercialising unit of the Karolinska Institute.
www.avexxin.com

Scandinavian BioPharma AS

Scandinavian BioPharma is currently developing a pharmaceutical  product for the treatment of mild to moderate psoriasis . The company was sold after Pilot studies.

Delante Health AS

SWG produces proprietary Omega-3 products/product lines based on high quality microencapsulated marine oils, packed in a user friendly effervescent / powder delivery form. The technology allows for the combination of water soluble and fat soluble nutrients in consumer friendly dietary supplement products. The first product, LipidFizz™ will offer omega-3 fatty acids with and without vitamins in a delivery form which has greater consumer appeal through improved product stability, taste and bioavailability, than current products.

Medtech  and diagnostics

Medstorm Innovation AS 
Medstorm has developed an instrument for objective measurement of pain. The instrument uses changes in skin conductivity as an indicator of perceived pain. Such pain measurements are relevant in medical treatment of humans under anaesthesia, for post-operative monitoring, for the prematurely born and for those with chronic pain. It is similarly applicable in veterinary medicine. The product is fully developed and commercially available.
www.med-storm.com

Volusense  AS
VoluSense as has developed a product, FloRight™, for non-invasive assessment without use of general anesthesia, of tidal breathing in neonates and children. FloRight measures the tidal breathing volume and flow, by a flexible vest around the torso without using the airway flow. Volusense facilitates diagnosis, treatment and follow-up in areas with high clinical value (obstructive, sleep and apnea). The product is fully developed, CE approved, and clinical documentation is being prepared.
www.volusense.com

ScreenCancer AS
ScreenCancer aims to augment global cancer screening rates by creating screening management services tailored to the needs of health plans, self-insured employers, and private individuals. The company’s competent and experienced management team aim to build the company as a preferred distribution channel through which a complete cancer screening program will be offered.
www.screencancer.com

GeneSeque AS
GeneSeque develops a technology that can, potentially, dramatically enhance the throughput capacity of the next generation DNA-sequencing technologies, thereby enabling further penetration of sequencing technology into new areas of application.

Marine

Blue Limit AS
Blue Limit has developed a unique feed concept particularly well suited for the early development phases of fish and shellfish larvae. The feed is unique in that it may potentially replace today’s live feed. The company is a commercialisation of research carried out by Fiskeriforskning in Bergen.
www.bluelimit.no

Seafarm Products AS
Seafarm Products develops a concept where fresh water and other ingredients are added to specialiced dry fish feed (pellets) enabling the fish to  maintain their natural salinity levels. Fresh water is added as part of the feeding process by means of a vacuum-system. The technology is currently being verified in several fish breeding plants, and will potentially increase efficiency and reduce the need for specialized fish feed.

Energy and cleantech

Sorbwater AS
Sorbwater Technology AS has developed an environmentally benign flocculation technology for removal of oil and other contaminants in water. The process is exceptionally effective and has the potential to reduce contaminants in produced water discharges from oil platforms from 30 ppm to 1 ppm. The technology is environmentally friendly and also approved for purification of drinking water.
www.sorbwater.com

Weyland AS
Weyland has developed and verified a  technology for producing (bio)ethanol from virtually any cellulose containing feedstock.  The core of the concentrated acid technology is the acid recycling process which is more efficient, more scalable and has less cost than current cellulosic ethanol technologies. A production facility is currently being built in Bergen, Norway.
www.weyland.no

Windsim AS
Windsim s Wind Farm Design Tool performs among other calculations of energy production in wind turbines and wind turbine farms and supplies software for such calculations. The company is a world leader in the use of tools based on Computational Fluid Dynamics (CFD) for wind energy and has over the years established a strong client base including the leading actors in wind power technology. Windsim’s products and technology directly increases the client’s energy production and profits, which explains why it has become one of the central technologies in development and monitoring of wind turbine parks.

www.windsim.com

EnSo AS
EnSo has developed a technology that uses electricity to neutralise unwanted marine organisms in ballast water. The equipment has the potential to become one of the world’s first systems to meet stringent international limitations on remnants of bio-active substances left behind in ports. EnSo collaborates with Protech AS and Christian Michelsen Research as well as with a Norwegian shipping company in development of a prototype.